Stoke Therapeutics (STOK) Total Liabilities (2018 - 2026)

Stoke Therapeutics has reported Total Liabilities for 9 years, with the latest figure at $48.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 14.81% year-over-year to $48.4 million; the trailing twelve-month figure through Mar 2026 stood at $48.4 million (down 14.81% YoY), and the FY2025 full-year result was $66.0 million, up 55.12% from the prior year.
• Total Liabilities for Q1 2026 stood at $48.4 million, down from $66.0 million in the prior quarter.
• The five-year high for Total Liabilities was $77.1 million in Q2 2022, with the low at $42.5 million in Q4 2024.
• Average Total Liabilities over 5 years is $63.2 million, with a median of $66.0 million recorded in 2025.
• Year-over-year, Total Liabilities surged 351.98% in 2022 and slumped 38.16% in 2024.
• Tracing STOK's Total Liabilities over 5 years: stood at $71.2 million in 2022, then fell by 3.43% to $68.8 million in 2023, then slumped by 38.16% to $42.5 million in 2024, then surged by 55.12% to $66.0 million in 2025, then dropped by 26.64% to $48.4 million in 2026.
• The last three Total Liabilities figures came in at $48.4 million (Q1 2026), $66.0 million (Q4 2025), and $52.2 million (Q3 2025), per Business Quant data.

Peer Comparison